The FDA has approved teplizumab to delay the onset of type 1 diabetes for both adults and children aged 8 years and older with stage 2 type 1 diabetes, according to an agency press release.
Tzield (teplizumab-mzwv, Provention Bio) injection is a humanized anti-CD3 monoclonal antibody designed to delay the development of type 1 diabetes in high-risk adults and children. “Tzield may deactivate the immune cells that attack insulin-producing cells, while increasing theproportion of cells that help moderate the immune response,” according to the release. Read more in Healio.